Pasithea Therapeutics Corporation

04/17/2026 | Press release | Distributed by Public on 04/17/2026 19:45

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Coastlands Capital LP
2. Date of Event Requiring Statement (Month/Day/Year)
04/09/2026
3. Issuer Name and Ticker or Trading Symbol
Pasithea Therapeutics Corp. [KTTA]
(Last) (First) (Middle)
601 CALIFORNIA STREET, SUITE 1210
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
SAN FRANCISCO, CA 94108
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3,735,035 I By Coastlands Capital LP(1)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Pre-funded Warrant (2) (2) Common Stock 11,233,334 $0.001 I By Coastlands Capital LP(1)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Coastlands Capital LP
601 CALIFORNIA STREET, SUITE 1210
SAN FRANCISCO, CA 94108
X

Signatures

/s/ Mark Shamia, Chief Operating Officer of the General Partner of Coastlands Capital LP 04/17/2026
**Signature of Reporting Person Date
/s/ Mark Shamia, Chief Operating Officer of the General Partner of Coastlands Capital Partners LP 04/17/2026
**Signature of Reporting Person Date
/s/ Mark Shamia, Chief Operating Officer of Coastlands Capital GP LLC 04/17/2026
**Signature of Reporting Person Date
/s/ Mark Shamia, Chief Operating Officer of Coastlands Capital LLC 04/17/2026
**Signature of Reporting Person Date
/s/ Matthew D. Perry 04/17/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 3 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
(2) The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Remarks:
Exhibit 99.1 - Agreement Regarding Joint Filing of Statement
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Pasithea Therapeutics Corporation published this content on April 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 18, 2026 at 01:45 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]